Compositions and methods for long-term culture of hepatocytes
A combination of small molecules stabilizes hepatocyte function in vitro for extended periods, enabling effective HBV modeling and drug development by maintaining key protein expression and metabolic activity.
Patent Information
- Application Number
- JP2021549702
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-02-26
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2039-02-26
AI Technical Summary
Current methods fail to maintain the long-term functionality of terminally differentiated cells, particularly human hepatocytes, limiting their application in modeling liver-tropic infections like HBV and hindering the differentiation of human pluripotent stem cells into mature cell types due to unstable culture conditions.
A composition comprising an activator of adenylate cyclase, a TGFβ inhibitor, a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor, such as forskolin, SB431542, DAPT, IWP2, and LDN193189, is used to culture hepatocytes, maintaining their functionality for extended periods.
The composition supports hepatocytes to express key functional proteins for up to 90 days, maintains drug metabolic activity, and allows stable HBV infection, providing a robust model for HBV research and drug development.
Smart Images

Figure 0007594789000016 
Figure 0007594789000017 
Figure 0007594789000018
Abstract
Description
[Technical field]
[0001] The present invention relates generally to the long-term maintenance of hepatocytes and the functional maturation of hepatocytes. [Background technology]
[0002] Terminally differentiated cells are functionally stable in vivo, a state that is highly dependent on precise spatiotemporal regulation by microenvironmental signals. Once isolated, cells undergo microenvironmental changes that result in functional regression. Long-term maintenance of terminally differentiated cells in vitro has proven difficult. Once isolated, these cells generally lose their specific functions (Haenseler et al., Stem Cell Reports 8, 1727-1742 (2017); Louch, et al., J Mol Cell Cardiol 51, 288-298 (2011); Ootani et al., Nat Med 15, 701-706 (2009); Shulman, et al., Methods Mol Biol 945, 287-302 (2013)). In particular, the failure to maintain primary human hepatocytes (PHHs) for the long term limits their application in modeling hepatotropic infections such as HBV infection, a disease of global prevalence (Zhong, et al., Clin. Chim. Acta: 412:1905-1911 (2011)). Na, a functional receptor for Hepatitis B virus (HBV), is a virulent receptor for HBV. +Advances such as the identification of the N-taurocholate cotransporting peptide (NTCP) have allowed the establishment of hepatocellular carcinoma cell lines to study HBV infection (Yan, et al., eLife 1, (2012)). However, studies investigating the HBV life cycle over time, especially the persistence of cccDNA, remain challenging (Liang et al., Hepatology 62, 1893-1908 (2015)). Although PHHs share highly similar infection characteristics with de novo human HBV infection and have been considered ideal for HBV modeling, their long-term utility is limited by their limited viability and unstable functional maintenance in vitro (Lu, et al., International journal of medical sciences 1, 21-33 (2004); Xia et al., J Hepatol 66, 494-503 (2017); Elaut et al., Curr Drug Metab 7, 629-660 (2006)). Therefore, the establishment of culture conditions for functional maintenance of authentic human hepatocytes may be beneficial for HBV research.
[0003] Furthermore, the lack of efficient culture conditions to stabilize the functionality of terminally differentiated cells has also limited the differentiation of human pluripotent stem cells (hPSCs) and the generation of functional mature cells by direct lineage reprogramming. Although hPSCs are considered an ideal potential cell source for generating large quantities of various human cell types, most hPSC-derived cells exhibited an immature phenotype when generated by current protocols (Hrvatin, et al., Proc Natl Acad Sci US A. 111 (8) 3038-3043 (2014)Takayama, et al., Drug Metab Pharmacokinet 32(1): 12-20 (2017)). One of the main reasons for the functional immaturity of hPSC-derived cells is the lack of available culture conditions that allow the acquisition of their terminal differentiation stage. Thus, the identification of culture conditions that support the maintenance of functionality of terminally differentiated cells may benefit both their in vitro application and generation.
[0004] There remains a need for cell culture methods that provide a solution for the long-term, functional maintenance of differentiated cell types, including human hepatocytes.
[0005] It is an object of the present invention to provide a method for long-term culturing of functionally differentiated cells in vitro.
[0006] It is also an object of the present invention to provide a composition for maintaining functionally differentiated cells in vitro for a long period of time.
[0007] It is also an object of the present invention to provide differentiated cells with improved maintenance of function in vitro. Summary of the Invention
[0008] Compositions for the long term maintenance of functional hepatocytes in culture, improved methods for maintaining functional hepatocytes in vitro, and functional hepatocyte cultures according to the methods disclosed herein are provided. .
[0009] The composition comprises at least an adenylate cyclase activator, a TGFβ inhibitor, a Notch inhibitor, a Wnt inhibitor, and / or a BMP inhibitor. In some preferred embodiments, the composition comprises a combination of an adenylate cyclase activator and a TGFβ inhibitor. In particularly preferred embodiments, the composition comprises a combination of at least one adenylate cyclase activator, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and one BMP inhibitor (herein, "5C"). The most preferred activator of adenylate cyclase activators is forskolin (FSK); a preferred TGFβ inhibitor is SB431542 (SB43); a preferred Notch inhibitor is DAPT; a preferred Wnt inhibitor is IWP2, and a preferred BMP inhibitor is LDN193189 (LDN). The combination of compounds is added to any hepatocyte culture medium in an effective amount to maintain functional hepatocyte function in vitro for an extended period of time.
[0010] The composition is used to improve the maintenance of functional hepatocytes in vitro.
[0011] Also provided are hepatocytes (herein "5C hepatocytes") obtained by the methods disclosed herein. When cultured by the methods disclosed herein, the hepatocytes exhibit improved maintenance of hepatocyte function in vitro. In a preferred embodiment, the 5C hepatocytes express at least six hepatocyte functional proteins at the same level as freshly isolated primary hepatocytes from the same organism after at least 60 days of culture. In a particularly preferred embodiment, the 5C hepatocytes express at least six hepatocyte functional proteins at the same level as freshly isolated primary hepatocytes from the same organism after at least 90 days of culture. In a particularly preferred embodiment, exemplary hepatocyte functional proteins include albumin (ALB), APOA2, APOB, F2, F10, cytochrome P450 (CYP)3A4, CYP1A2, CYP2C9, and UGT2B7.
[0012] A kit is provided for long-term maintenance of functional hepatocytes in culture. The kit includes an adenylate cyclase activator, a TGFβ inhibitor, a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor (herein, "5C"). The most preferred adenylate cyclase activator is forskolin; the preferred TGFβ inhibitor is SB43; the preferred Notch inhibitor is DAPT; the preferred Wnt inhibitor is IWP2, and the preferred BMP inhibitor is LDN.
[0013] Also provided is a method for identifying agents that improve the in vitro maintenance of functional differentiated cells, such as hepatocytes, comprising comparing the global gene expression profiles of freshly isolated primary hepatocytes with hepatocytes cultured for only 24 hours, and screening for small molecule targets involved in hepatocyte fate patterning, differentiation and reprogramming. [Brief description of the drawings]
[0014] [Figure 1] FIG. 1 shows the mRNA levels of functional marker genes analyzed by RNA sequencing (RNA-Seq) in hepatocytes cultured in HCM for 24 h (24-h cultured hepatocytes) and freshly isolated hepatocytes (F-PHH). [Figure 2A] Figures 2A and 2B show the identification of a TGF-β inhibitor (SB431542) as a factor partially supporting PHH maintenance in vitro. Figure 2A shows that genes enriched in the TGFβ signaling pathway were detected by RNA sequencing in hepatocytes cultured in HCM for 24 hours (24-hour cultured hepatocytes) and freshly isolated hepatocytes (F-PHH). [Figure 2B] Figure 2B shows gene expression of mesenchymal marker genes and hepatocyte function genes in PHHs cultured under different conditions detected by qRT-PCR, n = 2. Relative gene expression was normalized to F-PHHs. [Figure 3A] Figures 3A and 3B show that in vitro, the cAMP activator forskolin was identified as beneficial for PHH cultures. Screening of a pool of small molecules for candidates that effectively inhibited the expression of EMT master genes and maintained the expression of key hepatocyte genes. qRT-PCR analysis was performed on day 14 of culture; F-PHH was used as a positive control. Relative gene expression was normalized to Null. n=2. [Figure 3B] Figures 3A and 3B show that in vitro, the cAMP activator forskolin was identified as beneficial for PHH cultures. Screening of a pool of small molecules for candidates that effectively inhibited the expression of EMT master genes and maintained the expression of key hepatocyte genes. qRT-PCR analysis was performed on day 14 of culture; F-PHH was used as a positive control. Relative gene expression was normalized to Null. n=2. [Figure 4A]Figures 4A-4C show the effect of combined use of FSK and SB43 on PHH maintenance. Figure 4A is a line graph showing the MTT assay for analyzing cell viability under different culture conditions. n=3. [Figure 4B] Figure 4B shows that synergistic effects between SB43 and FSK (designated 2C) in regulating mesenchymal marker and hepatocyte function gene expression were observed as detected by RT-qPCR. Relative gene expression is normalized to F-PHH. [Figure 4C] Figure 4C shows qRT-PCR analysis of surrogate liver function markers in cultured hepatocytes after 4 weeks in culture. Relative gene expression was normalized to F-PHH. n=2. [Figure 4D] Figure 4D is a line graph showing the kinetics of ALB secretion in PHHs cultured under different conditions, n=3 independent batches. [Figure 4E] Figure 4E is a line graph showing albumin secretion and urea synthesis in cultured PHH, n=2. [Figure 4F] Figure 4F shows the drug metabolism activity of CYP enzymes in PHHs cultured under different conditions as measured by LC / MS. Specific activity of CYP3A4 was measured using testosterone (CYP3A4-T) and midazolam (CYP3A4-M). Results are shown in pmol / min per million cells. n=3. [Figure 4G] Figures 4G-I show induction of CYP450 activity in 2C-PHH detected by qRT-PCR (Figure 4G) and LC / MS (Figure 4H). Rif, rifampin; PB, phenobarbital; ETOH, ethanol; βNF, β-naphthoflavone. n≧2. (Figure 4I) Inhibition of CYP450 activity in 2C-PHH was detected by LC / MS in hepatocytes cultured with 2C. n=3. KC, ketoconazole; SX, sulfaphenazole; ANF, α-naphthoflavone. [Figure 4H]Figures 4G-I show induction of CYP450 activity in 2C-PHH detected by qRT-PCR (Figure 4G) and LC / MS (Figure 4H). Rif, rifampin; PB, phenobarbital; ETOH, ethanol; βNF, β-naphthoflavone. n≧2. (Figure 4I) Inhibition of CYP450 activity in 2C-PHH was detected by LC / MS in hepatocytes cultured with 2C. n=3. KC, ketoconazole; SX, sulfaphenazole; ANF, α-naphthoflavone. [Figure 4I] Figures 4G-I show induction of CYP450 activity in 2C-PHH detected by qRT-PCR (Figure 4G) and LC / MS (Figure 4H). Rif, rifampin; PB, phenobarbital; ETOH, ethanol; βNF, β-naphthoflavone. n≧2. (Figure 4I) Inhibition of CYP450 activity in 2C-PHH was detected by LC / MS in hepatocytes cultured with 2C. n=3. KC, ketoconazole; SX, sulfaphenazole; ANF, α-naphthoflavone. [Figure 4J] FIG. 4J shows the results of ELISA of human albumin in mouse serum 2 and 4 weeks after transplantation of PHHs cultured for 4 weeks. [Figure 4K] Figure 4K shows the expression of key CYP enzymes in PHHs cultured for 14 and / or 30 days in 2C condition, as detected by qRT-PCR. Two basal media, Williams Medium E (WME) and HCM, were applied. Relative gene expression is normalized to F-PHHs. [Figure 5A] Figures 5A-5E show the identification of the optimal configuration (5C condition) for maintaining PHH. Figure 5A is a scheme showing chemical screening to discover candidates that cooperate synergistically with SB43 and FSK. [Figure 5B] Figure 5B shows the effect of DAPT, LDN193189 and IWP2 alone and in combination with SB43 and FSK on EMT gene expression (suppress) or liver function gene expression (increase). Relative gene expression was normalized to DMSO. n=2. [Figure 5C]FIG. 5C shows the effect of three additional small molecules (IWP2, DAPT, and LDN193189) in combination with SB43 and FSK to reduce expression of the mesenchymal marker gene COL1A1 in cultured PHHs. qRT-PCR analysis was performed on day 14. Relative gene expression was normalized to FSK+SB43. n=3. [Figure 5D] Figure 5D shows the effect of replacing IWP2, DAPT, and LDN193189 with small molecules or cytokines targeting the same signaling pathways in suppressing EMT markers. Relative gene expression was normalized to FSK+SB43. n=3. [Figure 5E] Figure 5E shows the effect of each small molecule of 5C on the maintenance of PHH by assays that do not contain a single small molecule. Expression of hepatic transcription factors and functional genes was detected by qRT-PCR. Relative gene expression was normalized to 5C. n=2. [Figure 6A] Figure 6A shows qRT-PCR analysis of mesenchymal marker genes of Cryo-PHHs cultured for 2 weeks in hepatocyte culture medium (Null) and 5C culture conditions (5C). DMSO was used as a vehicle control. n=3. Similar results were obtained in three independent batches. [Figure 6B] Figures 6B and 6C show time course analysis of human albumin secretion and urea synthesis in freshly isolated PHH from an Asian donor (Figure 6B) and reconstituted cryopreserved PHH from a Caucasian donor (Figure 6C) maintained under 5C and control conditions, n=3. [Figure 6C] Figures 6B and 6C show time course analysis of human albumin secretion and urea synthesis in freshly isolated PHH from an Asian donor (Figure 6B) and reconstituted cryopreserved PHH from a Caucasian donor (Figure 6C) maintained under 5C and control conditions, n=3. [Figure 6D] Figures 6D and 6E show a study in which PHH were maintained with 5C for over 2 months. Figure 6D shows albumin secretion and urea synthesis assays of PHH cultured under 5C conditions over 60 days. n=3. Similar results were obtained in two independent batches. [Figure 6E]Figure 6E shows qRT-PCR analysis of key hepatic genes in PHHs cultured under 5C conditions (5C-PHHs) at days 60 and 90. Relative expression levels were normalized to F-PHHs. n=2. [Figure 7] Figure 7 shows hierarchical clustering to compare the global gene expression profiles of PHHs cultured under different conditions, hepatocytes derived from pluripotent stem cells (hiPSC-Hep_rep1 / 2 / 3 / 4), freshly isolated human hepatocytes (PHH0d) and adult liver tissue. Three independent batches of PHHs were applied, and the corresponding adult liver tissue was used as a positive control. The expression profiles of PHH0d and hiPSC-Hep_rep1 / 2 / 3 / 4 were RNA-seq data obtained from Gao et al., Stem Cell Reports 9, 1813-1824 (2017). [Figure 8A] Figure 8A shows gene expression analysis of hepatic surrogate and mesenchymal markers in 5C-PHH and PHH maintained under sandwich culture by qRT-PCR. qRT-PCR analysis was performed on day 15. Relative expression levels were normalized to F-PHH. n=2. [Figure 8B] Figure 8B shows gene expression analysis of hepatic transcription factors by qRT-PCR. Relative expression levels were normalized to F-PHH. n=2. Similar results were obtained in two independent batches. [Figure 8C] FIG. 8C shows the effect of 5C on drug metabolizing activity of cultured human hepatocytes measured in vitro as gene expression analysis of the five core CYP450 enzymes by qRT-PCR after 4 weeks of culture, n=3. [Figure 8D] Figure 8D shows qRT-PCR analysis of key phase II enzymes and phase III transporters in 5C-PHH after 4 weeks of culture. Relative expression levels were normalized to F-PHH. n=2. Similar results were obtained in at least three independent batches. [Figure 8E]Figure 8E shows dynamic gene expression analysis of drug metabolism-related genes by qRT-PCR in Cryo-PHH under different conditions. Regenerated cryopreserved PHH showed severe cell death after 1 week of culture in control conditions (null and DMSO), so data after day 10 are not shown. Relative gene expression was normalized to Cryo-PHH. n=2. [Figure 8F] FIG. 8F shows the effect of 5C on the drug metabolism activity of cultured human hepatocytes measured in vitro as drug metabolism activity of the five core CYP450 enzymes by LC-MS after 2 weeks of culture. n=3. Not detected data are labeled "nd." [Figure 9A] Figures 9A-F show the support of 5C for the entire life cycle of HBV infection in PHH. Figure 9A: Gene expression analysis of NTCP by qRT-PCR. n=3. [Figure 9B] Figure 9B: Kinetics of HBV antigen (HBsAg and HBeAg) formation in supernatants of infected PHH cultured under different conditions. n=3. [Figure 9C] Fig. 9C: Kinetics of HBVRNA formation in PHHs cultured under different conditions analyzed by qRT-PCR. n=2. [Figure 9D] Fig. 9D: Kinetics of HBV DNA formation in supernatants of infected PHH cultured under different conditions. n=3. [Figure 9E] FIG. 9E: Kinetics of cccDNA formation in 5C-PHH detected by qPCR. n=2. [Figure 9F] Figures 9F and 9G show the detection of HBeAg (n=3) (Figure 9F) and viral DNA (n=2) (Figure 9G) in PHH inoculated with supernatants from HVB-infected 5C-PHH. [Figure 9G] Figures 9F and 9G show the detection of HBeAg (n=3) (Figure 9F) and viral DNA (n=2) (Figure 9G) in PHH inoculated with supernatants from HVB-infected 5C-PHH. [Figure 9H]Figure 9H is a Southern blot analysis of HBV cccDNA in infected 5C-PHH. HBV DNA was extracted by the core DNA extraction method (lanes 1 and 4) and the modified Hirt DNA extraction method (lanes 2, 3, 5, and 6). To confirm the identity of cccDNA, Hirt DNA preparations extracted from 5C-PHH with or without treatment (lanes 2 and 5) and with SpeI digestion (lanes 3 and 6) were separated on an agarose gel. Dpi is days postinfection. [Figure 10A] Figures 10A-B show HBV infection of 5C-PHH at reduced multiplicity of infection (MOI). HBV infection was detected by secreted HBV antigens (HBsAg and HBeAg) (Figure 10A) and intracellular HBV transcripts (Figure 10B). n=3. [Figure 10B] Figures 10A-B show HBV infection of 5C-PHH at reduced multiplicity of infection (MOI). HBV infection was detected by secreted HBV antigens (HBsAg and HBeAg) (Figure 10A) and intracellular HBV transcripts (Figure 10B). n=3. [Figure 11A] Figure 11A shows HBsAg and HBeA in PHH isolated from Caucasian and Asian donors, infected with HBV B or C, and cultured at 5C, n=3. [Figure 11B] Figures 11B-D show the effect of 5C-PHH infected with HBV particles generated from HepAD38. (Figure 11B) Time course analysis of HBsAg and HBeAg in the supernatant of 5C-PHH. n=3. (Figure 11C) HBV RNA, (Figure 11D) intracellular HBV DNA and cccDNA were detected at 7 dpi and 18 dpi. n=3. Similar results were obtained in at least three independent batches. [Figure 11C] Figures 11B-D show the effect of 5C-PHH infected with HBV particles generated from HepAD38. (Figure 11B) Time course analysis of HBsAg and HBeAg in the supernatant of 5C-PHH. n=3. (Figure 11C) HBV RNA, (Figure 11D) intracellular HBV DNA and cccDNA were detected at 7 dpi and 18 dpi. n=3. Similar results were obtained in at least three independent batches. [Figure 11D] Figures 11B-D show the effect of 5C-PHH infected with HBV particles generated from HepAD38. (Figure 11B) Time course analysis of HBsAg and HBeAg in the supernatant of 5C-PHH. n=3. (Figure 11C) HBV RNA, (Figure 11D) intracellular HBV DNA and cccDNA were detected at 7 dpi and 18 dpi. n=3. Similar results were obtained in at least three independent batches. [Figure 11E] Figures 11E-F show that neutralizing antibodies (anti-S antibodies) block HBV spread in 5C-PHH. (Figure 11E) Time course analysis of HBeAg in 5C-PHH infected at various MOIs. Neutralizing antibodies (anti-S antibodies) were added from 1 Dpi. n=3. (Figure 11F) Quantification of HBcAg positive cells at Dpi28. n=3. [Figure 11F] Figures 11E-F show that neutralizing antibodies (anti-S antibodies) block HBV spread in 5C-PHH. (Figure 11E) Time course analysis of HBeAg in 5C-PHH infected at various MOIs. Neutralizing antibodies (anti-S antibodies) were added from 1 Dpi. n=3. (Figure 11F) Quantification of HBcAg positive cells at Dpi28. n=3. [Figure 12A] Figures 12A-D show the response of HBV-infected 5C-PHH to anti-HBV drugs. Figures 12A-D show the effect of anti-HBV drugs (ETV, LAM, IFN-α) on HBV antigen (HBsAg and HBeAg) (Figure 12A), HBV RNA (detected at 16 Dpi) (Figure 12B), HBV DNA (detected at 21 Dpi) (Figure 12C), and HBVcccDNA (detected at 34 Dpi) (Figure 12D) in infected 5C-PHH. [Figure 12B] Figures 12A-D show the response of HBV-infected 5C-PHH to anti-HBV drugs. Figures 12A-D show the effect of anti-HBV drugs (ETV, LAM, IFN-α) on HBV antigen (HBsAg and HBeAg) (Figure 12A), HBV RNA (detected at 16 Dpi) (Figure 12B), HBV DNA (detected at 21 Dpi) (Figure 12C), and HBVcccDNA (detected at 34 Dpi) (Figure 12D) in infected 5C-PHH. [Figure 12C]Figures 12A-D show the response of HBV-infected 5C-PHH to anti-HBV drugs. Figures 12A-D show the effect of anti-HBV drugs (ETV, LAM, IFN-α) on HBV antigen (HBsAg and HBeAg) (Figure 12A), HBV RNA (detected at 16 Dpi) (Figure 12B), HBV DNA (detected at 21 Dpi) (Figure 12C), and HBVcccDNA (detected at 34 Dpi) (Figure 12D) in infected 5C-PHH. [Figure 12D] Figures 12A-D show the response of HBV-infected 5C-PHH to anti-HBV drugs. Figures 12A-D show the effect of anti-HBV drugs (ETV, LAM, IFN-α) on HBV antigen (HBsAg and HBeAg) (Figure 12A), HBV RNA (detected at 16 Dpi) (Figure 12B), HBV DNA (detected at 21 Dpi) (Figure 12C), and HBVcccDNA (detected at 34 Dpi) (Figure 12D) in infected 5C-PHH. [Figure 13A] Figure 13A is a time course analysis of the inflammatory response in cultured 5C-PHH. Relative gene expression was normalized to 5C. n=3. Similar results were obtained in three independent batches. [Figure 13B] Figure 13B-D: Comparison of 5C with three other reported PHH culture conditions for long-term hepatocyte maintenance and HBV tolerance: condition 1, C1 (Winer et al., Nat Comm. 8:125 (2017)); condition 2, C2 (Lucifora, et al., Science, 343:1221-28 (2014)) and condition 3, C3 (Xia, et al., J. Hepatol., 66:494-503 (2017)). (Figure 13B) qRT-PCR analysis of liver function gene expression in PHH cultured under different culture conditions. n=3. (Figure 13C) Time course analysis of human albumin secretion and urea synthesis in PHH cultured under different culture conditions. n=3. (Figure 13D) Time course analysis of HBeAg. PHH were infected with plasma from a hepatitis B patient and further cultured under different conditions for a long period of time. n=3. Similar results were obtained with three independent batches. [Figure 13C]Figure 13B-D: Comparison of 5C with three other reported PHH culture conditions for long-term hepatocyte maintenance and HBV tolerance: condition 1, C1 (Winer et al., Nat Comm. 8:125 (2017)); condition 2, C2 (Lucifora, et al., Science, 343:1221-28 (2014)) and condition 3, C3 (Xia, et al., J. Hepatol., 66:494-503 (2017)). (Figure 13B) qRT-PCR analysis of liver function gene expression in PHH cultured under different culture conditions. n=3. (Figure 13C) Time course analysis of human albumin secretion and urea synthesis in PHH cultured under different culture conditions. n=3. (Figure 13D) Time course analysis of HBeAg. PHH were infected with plasma from a hepatitis B patient and further cultured under different conditions for a long period of time. n=3. Similar results were obtained with three independent batches. [Figure 13D] Figure 13B-D: Comparison of 5C with three other reported PHH culture conditions for long-term hepatocyte maintenance and HBV tolerance: condition 1, C1 (Winer et al., Nat Comm. 8:125 (2017)); condition 2, C2 (Lucifora, et al., Science, 343:1221-28 (2014)) and condition 3, C3 (Xia, et al., J. Hepatol., 66:494-503 (2017)). (Figure 13B) qRT-PCR analysis of liver function gene expression in PHH cultured under different culture conditions. n=3. (Figure 13C) Time course analysis of human albumin secretion and urea synthesis in PHH cultured under different culture conditions. n=3. (Figure 13D) Time course analysis of HBeAg. PHH were infected with plasma from a hepatitis B patient and further cultured under different conditions for a long period of time. n=3. Similar results were obtained with three independent batches. [Figure 14A]Figures 14A-C show the application of 5C culture conditions to different plating formats. PHHs were plated in microwell plates (96-well and 384-well plates) and further cultured in 5C. (Figure 14A) After 2 weeks of culture, EMT markers and liver function genes were analyzed. (Figure 14B) After 7 and 14 days of culture, ALB secretion and urea synthesis were detected. (Figure 14C) HBV infection was performed in microwell plates and HBsAg and HBeAg were analyzed. n=3. Similar results were obtained in two independent batches. [Figure 14B] Figures 14A-C show the application of 5C culture conditions to different plating formats. PHHs were plated in microwell plates (96-well and 384-well plates) and further cultured in 5C. (Figure 14A) After 2 weeks of culture, EMT markers and liver function genes were analyzed. (Figure 14B) After 7 and 14 days of culture, ALB secretion and urea synthesis were detected. (Figure 14C) HBV infection was performed in microwell plates and HBsAg and HBeAg were analyzed. n=3. Similar results were obtained in two independent batches. [Figure 14C] Figures 14A-C show the application of 5C culture conditions to different plating formats. PHHs were plated in microwell plates (96-well and 384-well plates) and further cultured in 5C. (Figure 14A) After 2 weeks of culture, EMT markers and liver function genes were analyzed. (Figure 14B) After 7 and 14 days of culture, ALB secretion and urea synthesis were detected. (Figure 14C) HBV infection was performed in microwell plates and HBsAg and HBeAg were analyzed. n=3. Similar results were obtained in two independent batches. [Figure 15A]Figures 15A-C show the effect of 5C on HCV infection in Cryo-PHH. Cryo-PHH were infected with HCVcc (MOI=2) and further cultured in 5C with or without DCV treatment (Figures 15A and B). Secreted HCV products (Figure 15A) and intracellular HCV RNA (Figure 15B) were measured. n=3. Figure 15C shows qRT-PCR analysis of ISG expression in HCV-infected 5C-PHH (here designated Jc1G) and uninfected 5C-PHH. n=3. [Figure 15B] Figures 15A-C show the effect of 5C on HCV infection in Cryo-PHH. Cryo-PHH were infected with HCVcc (MOI=2) and further cultured in 5C with or without DCV treatment (Figures 15A and B). Secreted HCV products (Figure 15A) and intracellular HCV RNA (Figure 15B) were measured. n=3. Figure 15C shows qRT-PCR analysis of ISG expression in HCV-infected 5C-PHH (here designated Jc1G) and uninfected 5C-PHH. n=3. [Figure 15C] Figures 15A-C show the effect of 5C on HCV infection in Cryo-PHH. Cryo-PHH were infected with HCVcc (MOI=2) and further cultured in 5C with or without DCV treatment (Figures 15A and B). Secreted HCV products (Figure 15A) and intracellular HCV RNA (Figure 15B) were measured. n=3. Figure 15C shows qRT-PCR analysis of ISG expression in HCV-infected 5C-PHH (here designated Jc1G) and uninfected 5C-PHH. n=3. [Figure 16] Figure 16 shows the kinetics of expression of CYP enzymes, drug-metabolizing nuclear receptors, and a panel of key transcription factors in human embryonic stem cell-derived hepatocytes (hESC-Heps) cultured under 2C conditions. Relative gene expression was detected by qRT-PCR and normalized to day 0. n=2.
[0015] [Detailed Description of the Invention] Here, we demonstrate that this fundamental problem can be overcome by modulating cell signaling pathways with a combination of small molecules in primary human hepatocytes (PHHs). We identified a five-chemical condition (5C) for long-term functional maintenance of PHHs. PHHs cultured in 5C exhibited global gene expression profiles and hepatocyte-specific functions similar to freshly isolated human hepatocytes. PHHs cultured in 5C were permissive to hepatitis B virus (HBV) and efficiently recapitulated the entire course of HBV infection over a 4-week period while maintaining persistently detectable HBV covalently closed circular DNA (cccDNA). This study provided an efficient platform for understanding HBV pathology and antiviral drug screening, and this chemical approach was applicable to the maintenance of other functional cell types in vitro.
[0016] The disclosed culture conditions also maintained and promoted hESC-hepatocytes approaching a mature stage. Under our conditions, hESC-hepatocytes were maintained for over one month, and functional maturation of long-term cultured hESC-hepatocytes was observed. hESC-hepatocytes cultured under our conditions progressively expressed a series of CYP enzymes, demonstrating functional maturation of hESC-hepatocytes approaching a mature-like stage that promoted the generation of functionally mature cells from hPSCs.
[0017] I. Definition As used herein, "5C medium" refers to a basal cell culture medium for hepatocytes supplemented with at least one activator of adenylate cyclase, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and one BMP inhibitor, such as HCM medium (Hepatocyte Culture Medium, Lonza) or Williams E medium, containing 2% B27 (Gibco), 1% GlutaMAX, supplemented with forskolin, SB431542, DAPT, IWP2, and LDN193189.
[0018] As used herein, "culture" refers to a population of cells that has been grown in a medium and optionally passaged. A cell culture may be a primary culture (e.g., a culture that has not been passaged) or a secondary or subsequent culture (e.g., a population of cells that has been passaged or passed through one or more passages).
[0019] As used herein, "downregulation" or "downregulating" refers to the process by which a cell reduces the amount and / or activity of a cellular component, such as, for example, DNA, RNA, or protein, in response to an external variable.
[0020] As used herein, the term "induced hepatocytes" (iHep) refers to cells that are not naturally occurring hepatocytes, but are artificially derived from non-hepatic cells.
[0021] The terms "oligonucleotide" and "polynucleotide" generally refer to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA.Thus, for example, as used herein, polynucleotide refers to, among others, single-stranded and double-stranded DNA, DNA that is a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, and RNA that is a mixture of single-stranded and double-stranded regions, hybrid molecules that contain DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single-stranded and double-stranded regions.The terms "nucleic acid" or "nucleic acid sequence" also encompass polynucleotides as defined above.
[0022] As used herein, the term polynucleotide includes the above DNA or RNA that contains one or more modified bases.Thus, DNA or RNA with backbones modified for stability or other reasons is a "polynucleotide" as the term is intended herein.In addition, DNA or RNA that contains unusual bases such as inosine or modified bases such as tritylated bases, to name just two examples, is a polynucleotide as the term is used herein.
[0023] As used herein, "reprogramming" refers to the conversion of one particular cell type to another cell type. For example, a non-hepatocyte cell can be morphologically and functionally reprogrammed into a hepatocyte-like cell.
[0024] The term "upregulate expression" means, for example, to affect expression, to induce expression or activity, or to induce increased / greater expression or activity compared to untreated cells.
[0025] As used herein, "upregulation" or "upregulating" refers to the process by which a cell increases the amount and / or activity of a cellular component, e.g., DNA, RNA, or protein, in response to an external variable.
[0026] II. Composition The composition comprises a hepatocyte culture medium supplemented with at least one adenylate cyclase activator, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and / or one BMP inhibitor.
[0027] In some preferred embodiments, the compositions comprise a combination of an activator of adenylate cyclase and a TGFβ inhibitor (herein, 2C).
[0028] In a more preferred embodiment, the composition comprises an activator of adenylate cyclase and a TGFβ inhibitor in combination with at least one agent selected from the group consisting of a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor.
[0029] In a particularly preferred embodiment, the composition comprises a combination of at least one adenylate cyclase activator, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and one BMP inhibitor (herein "5C"). The most preferred adenylate cyclase activator is forskolin; the preferred TGFβ inhibitor is SB43; the preferred Notch inhibitor is DAPT; the preferred Wnt inhibitor is IWP2, and the preferred BMP inhibitor is LDN193189.
[0030] In some embodiments, the combination of compounds is added to any hepatocyte culture medium in an amount effective to maintain long-term functional hepatocyte function in vitro, as measured as an amount effective to maintain expression of at least six hepatocyte functional proteins at the same level as freshly isolated primary hepatocytes from the same organism after at least 60 days of culture.
[0031] Useful cell culture media for hepatocyte culture are known in the art (herein "Hepatocyte Basal Medium"). Useful examples include, but are not limited to, Williams Medium E with B27, Glutmax and Penicillin Strep; Hepatocyte Medium; Dulbecco's Modified Eagle Medium ("DMEM") and Ham's F12 medium, either alone or in combination; Waymouth's MB-752 / 1, Ham's F12, RPMI1640, Dulbecco's Modified Eagle Medium, Leibovitz'L15, HBM™ (Lonza), Hepatocyte Basal Medium WAJC110 (MyBiosouirce.com) and modified Chee's medium.
[0032] Hepatocyte Culture Media Supplement cAMP agonists A preferred cAMP agonist is forskolin, used at a concentration ranging from 2 to 100 μM, preferably 5 to 50 μM, more preferably 18 to 22 μM. However, any cAMP agonist can be included in the cocktail of CINPs disclosed herein. Examples include, but are not limited to, prostaglandin E2 (PGE2), rolipram, genistein, and cAMP analogs such as DBcAMP or 8-bromo-cAMP.
[0033] TGF-β inhibitors The TGFβ inhibitor, in some embodiments, preferably inhibits the TGFβ type 1 receptor activin receptor-like kinase (ALK) 5, and in other embodiments, may further inhibit ALK4 and nodal receptor 1 receptor ALK7. The TGFβ receptor inhibitor may be SB431542 (4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide), the structure of which is shown below, and is used at a concentration of 2-50 μM, preferably 2-15 μM, and more preferably 8-12 μM. [ka]
[0034] Other TGFβ inhibitors are known in the art and commercially available, such as: E-616452 ([2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine]; 83-01 [3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide]; SB505124 [2-[4-(1,3-benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazole]; -5-yl]-6-methyl-pyridine]; GW788388 [4-[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide]; and SB525334 [6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline], and dorsomorphin.
[0035] Notch inhibitors The compositions preferably comprise one or more Notch inhibitors, more preferably DAPT ((2S)-N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine 1,1-dimethylethyl ester), the structure of which is shown below, used at a concentration of between 0.1 μM and 10 μM, preferably between 0.5 μM and 2.5 μM, and more preferably between 1 μM and 2 μM. [ka]
[0036] Other Notch inhibitors are known in the art. A representative example is MK0752, the structure of which is shown below, which is used at a concentration of between 0.02 μM and 20 μM, preferably between 0.2 μM and 10 μM, more preferably between 1 μM and 5 μM. [ka]
[0037] RO4929097 (the structure of which is shown below) is used at a concentration between 0.02 μM and 20 μM, preferably between 0.2 μM and 10 μM, more preferably between 1 μM and 5 μM. [ka]
[0038] XXi ((S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide) (used at a preferred concentration between 0.2 and 1 μM); DBZ (N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenzo[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3, 5-difluorobenzeneacetamide); SAHM1 (peptide sequence AERLRRRIXLCRXHHST with the following modifications: (Ala-1 = N-terminal Ac, Ala-1 = β-Ala, X = (S)-2-(4-pentenyl)alanine, X-9 and X-13 are bonded to each other by a double bond); and FLI06 (cyclohexyl 1,4,5,6,7,8-hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylate).
[0039] Wnt inhibitors The disclosed compositions can include one or more Wnt inhibitors. A preferred Wnt inhibitor is IWP2 (N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide), the structure of which is shown below, and is used at a concentration of, for example, between 0.01 μM and 2.5 μM, preferably between 0.1 μM and 1 μM, and more preferably between 0.5 μM and 1 μM. [ka]
[0040] IWP2 inhibits Wnt processing and secretion. It inactivates PORCN, a membrane-bound O-acyltransferase (MBOAT), and selectively inhibits palmitoylation of Wnt. It blocks Wnt-dependent phosphorylation of the Lrp6 receptor and Dvl2, and accumulation of β-catenin.
[0041] Other Wnt signaling inhibitors are known in the art. Representative examples include Dickkopf-related protein 1 (DKK1) (used at a preferred concentration of between 10 ng / mL and 1000 ng / mL, more preferably at a concentration of between 50 ng / mL and 150 ng / mL); IWR1 (4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-N-8-quinolinyl-benzamide) (used at a preferred concentration of between 0.1 μM and 5 μM, more preferably at a concentration of between 1 μM and 2 μM); Wnt-C59 (4-(2-methyl-4-pyridinyl)-N-[4-(3- IWP12 (N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-3,6-dimethyl-4-oxothieno[3,2-d]pyrimidin-2-yl)thio]acetamide) and IWP23 (N-(5-phenyl-2-pyridinyl)-2-[(3,4,6,7-tetrahydro-3,6-dimethyl-4-oxothieno[3,2-d]pyrimidin-2-yl)thio]acetamide).
[0042] BMP inhibitors The compositions include one or more BMP inhibitors. A preferred BMP inhibitor is LDN193189 2HCl (4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride), the structure of which is shown below, used, for example, at a concentration between 0.01 μM and 0.5 μM, preferably between 0.05 μM and 0.25 μM, and more preferably between 0.1 μM and 0.2 μM. [ka]
[0043] LDN193189 is a potent and selective ALK2 and ALK3 inhibitor (IC 50 values are 5 and 30 nM, respectively); inhibits BMP4-mediated Smad1 / 5 / 8 activation. Shows over 200-fold selectivity for BMP signaling over TGF-β signaling. Also shows selectivity for AMPK, PDGFR, and MAPK signaling.
[0044] Other useful BMP inhibitors are known in the art. Representative examples include, but are not limited to, LDN212854 (5-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline), the structure of which is shown below, and is used at a preferred concentration of between 0.05 μM and 5 μM, more preferably between 0.1 μM and 2 μM. [ka]
[0045] Noggin is used at a preferred concentration between 10 ng / mL and 1000 ng / mL, more preferably at a concentration between 50 ng / mL and 500 ng / mL; Dorsomorphin dihydrochloride (6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidine dihydrochloride); and K02288 (3-[(6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenol.
[0046] B. Hepatocytes cultured in medium supplemented with small molecules Hepatocytes cultured using the supplemented hepatocyte culture media disclosed herein maintain functional hepatocytes in vitro for extended periods of time, as measured in terms of hepatocytes having at least one characteristic selected from the group consisting of hepatocyte morphology (polygonal shape), established hepatocyte functions such as albumin secretion and urea synthesis, and expression of at least one known hepatocyte marker. Expression levels of hepatocyte markers can be determined by measuring expression levels of oligonucleotides encoding the hepatocyte marker, or by measuring protein levels using methods known in the art and exemplified herein.
[0047] In one embodiment, the ability to maintain functional hepatocytes in vitro for a long period of time is measured in that hepatocytes have at least one of the characteristics listed above after at least 2 weeks of culture.In some embodiments, said hepatocytes have at least one of the characteristics listed above after 3 weeks of culture.For example, said hepatocytes have at least one of the characteristics listed above at improved levels after 4 weeks of culture, 5 weeks of culture, 6 weeks of culture, 7 weeks of culture, 8 weeks of culture, 9 weeks of culture, and 90 days or more of culture, when compared with hepatocytes obtained from the same organism and cultured without supplementing cell culture medium with the hepatocyte culture supplement disclosed herein.
[0048] Hepatocyte markers that can be used to determine long-term maintenance of functional hepatocytes in culture include cytochrome P450 (CYP) 3A4; CYP1A2; CYP2C9; CYP2D6; CYP2B6; CYP2C8; CSP1; CYP2C19; UDP-glucuronosyltransferase (UGT) 1A3; UGT1A4; UGT2B15; UGT2B7; NTCP (Na +-taurocholic acid cotransport peptide); ABCG2 (ATP-binding cassette superfamily G member 2, also known as BCRP); MRP2 (multidrug resistance-associated protein 2); organic anion transporting polypeptide (OATP) 1B1; APOA2, APOB, F2 (clotting factor II), F10 (clotting factor X). Thus, hepatocytes cultured in the supplemented hepatocyte culture medium disclosed herein exhibit improved expression of at least one of P450 (CYP) 3A4; CYP1A2; CYP2C9; CYP2D6; CYP2B6; CYP2C19 when compared to hepatocytes from the same organism cultured using the same basal hepatocyte culture medium without supplementation with the small molecules disclosed herein. Improved expression can be measured as a statistically significant difference in the level of expression.
[0049] In some preferred embodiments, hepatocytes cultured by the methods disclosed herein express at least one of the hepatocyte markers listed above at levels equivalent (measured as without statistical significance) or greater when compared to the levels expressed by freshly isolated hepatocytes from the same organism.
[0050] In particularly preferred embodiments, hepatocytes maintained in vitro using the supplemented cell culture media disclosed herein express at least one, at least two, at least three, at least four, at least five, or at least six of the following hepatocyte markers: APOA2, APOB, F2, F10, CYP3A4, CYP1A2, CYP2C9, and UTG2B7, at levels comparable to freshly isolated hepatocytes obtained from the same organism over 90 days in culture.
[0051] Hepatocytes cultured in 5C have metabolically active CYP3A4, CYP1A2, CYP2C9, CYP2D6, and CYP2B6 at levels comparable to those of F-PHH after 2 weeks of culture. In contrast, metabolic activity of PHH cultured in control (hepatocyte culture medium without 5C supplementation) is barely detectable at the same time point.
[0052] III.How to use A. Hepatocyte culture The disclosed cell culture compositions are used in hepatocyte culture for long-term maintenance of functional hepatocytes in vitro. The disclosed cell culture compositions can be used not only for maintenance of hepatocytes, but also for functional maturation of hepatocytes (e.g., hepatocytes generated from differentiation or reprogramming).
[0053] The disclosed methods in some embodiments do not rely on co-culture of hepatocytes with a second cell type, such as satellite cells. However, in other embodiments, a co-culture format including a second cell type, such as satellite cells, may be used. In some embodiments, the cell culture is a sandwich culture format, for example, as disclosed in Dunn, et al., Biotechnol. Prog., 7:237-245 (1991).
[0054] Hepatocytes from any source can be cultured using the supplemented cell culture medium disclosed herein. Hepatocytes can be isolated from animals, such as mice, livestock, primates, or humans. In preferred embodiments, the hepatocytes are isolated from humans. Hepatocytes can also be induced hepatocytes (iHep). For example, the iHep can be obtained by reprogramming or differentiation. In some preferred embodiments, the hepatocytes are primary hepatocytes, and in some embodiments, the hepatocytes can be cryopreserved hepatocytes.
[0055] Primary hepatocytes can be isolated from donors using methods known in the art, for example, using a two-step collagenase perfusion method (Lee et al., J Vis Exp, 79, e50615 (2013)). For example, liver samples are perfused with an appropriate perfusion buffer (PB) to remove blood cells, followed by treatment with perfusion buffer + EDTA (PBE) and then perfusion buffer + collagenase (PBC). An exemplary perfusion buffer is (0.15M NaCl; 5mM KCl; 25mM NaHCO3; 5mM glucose; 20mM Hepes). The hepatocyte suspension is washed with a basal hepatocyte medium, e.g., Williams medium E, filtered, and the isolated hepatocytes are seeded into tissue culture plates / matrix used for hepatocyte culture and cultured in basal hepatocyte culture medium supplemented with one activator of adenylate cyclase, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and / or one BMP inhibitor.
[0056] In some embodiments, isolated hepatocytes are seeded onto a monolayer of collagen, and a second layer of collagen may or may not be added to provide a sandwich-type hepatocyte culture. Hepatocytes can also be cultured in morphologies such as hepatic spheroids when cultured on soft or non-adherent extracellular matrices.
[0057] Preferred culture conditions include at 37° C. in a humidified incubator with 5% CO 2 .
[0058] The basal hepatocyte culture medium is supplemented with at least one of an adenylate cyclase activator, a TGFβ inhibitor, a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor. In some preferred embodiments, the basal hepatocyte culture medium is supplemented with a combination of an adenylate cyclase activator and a TGFβ inhibitor.
[0059] In a more preferred embodiment, the basal hepatocyte culture medium is supplemented with an activator of adenylate cyclase in combination with at least one agent selected from the group consisting of a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor, and a TGFβ inhibitor.
[0060] In a particularly preferred embodiment, the basal hepatocyte culture medium is supplemented with at least a combination of one adenylate cyclase activator, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and one BMP inhibitor (herein "5C"). The most preferred adenylate cyclase activator is forskolin; the preferred TGFβ inhibitor is SB431542 (SB43); the preferred Notch inhibitor is DAPT; the preferred Wnt inhibitor is IWP2, and the preferred BMP inhibitor is LDN193189.
[0061] B. Research-related uses The studies disclosed herein demonstrate that human hepatocytes cultured by the methods disclosed herein are capable of retaining drug metabolizing activity for extended periods of time, thus providing a platform for pharmaceutical applications.
[0062] (i) Drug testing Hepatocytes play an important role in drug development because the liver plays a central role in the metabolic activity of drugs. Currently, the main cause of failure of drug candidates is their non-ideal ADME (absorption, distribution, metabolism, excretion). The backbone of drug discovery research is the metabolic and toxic effects of candidate drugs in hepatocytes, the human liver parenchymal cells involved in all of drug metabolism. Currently, the main hepatocytes used in in vitro drug development are primary human adult hepatocytes. Due to the difficulty of maintaining the function of primary hepatocytes in vitro, the application of drug candidates in drug development is extremely limited. Hepatocytes cultured by the methods disclosed herein express drug metabolism genes for long periods in culture, maintain metabolic activity for long periods in culture, and can be used for in vitro drug metabolism studies. As described above, hepatocytes cultured at 5C have metabolically active CYP3A4, CYP1A2, CYP2C9, CYP2D6, and CYP2B6 at levels comparable to F-PHH after two weeks of culture. In contrast, metabolic activity of PHH cultured in control (hepatocyte culture medium without 5C supplementation) is barely detectable at the same time point.
[0063] (ii) Liver disease model A problem encountered in research involving infectious diseases is the lack of suitable models. In vitro cultured hepatocytes can be used as cell models for the study of infection by parasites of the liver, such as hepatitis viruses (hepatitis B, C, or D infection), infection by parasites that cause malaria. These models can provide an effective platform for the development of vaccines and drugs to treat infectious diseases, especially diseases that infect the liver.
[0064] The hepatocytes cultured by the method disclosed herein can be used as an in vitro model for studying liver disease, such as viral infection of the liver.A preferred example is infection and disease progression by hepatitis viruses.In a particularly preferred embodiment, the hepatocytes can serve as a model for hepatitis B and C infection and disease progression.
[0065] Thus, the hepatocytes disclosed herein can be used as an in vitro model of hepatocyte infection by a parasite produced by a method comprising inoculating the disclosed hepatocytes with a hepatic parasite for a period of time effective for infection by the parasite, and culturing the parasite-infected cells in vitro in a supplemented hepatic basal medium for hepatocyte culture (HC).
[0066] HBV products (secreted HBsAg, HBsAg and DNA particles) were detected in the supernatant of 5C-PHH culture, and the data of this application show that inoculation of PHH (cultured by the method disclosed herein) with HBV particles produced in plasma or cell culture from HBV-infected patients resulted in successful HBV infection. This high level of HBV product production was sustained for at least one month in 5C-PHH. Formation of HBVcccDNA could be detected at week 4 in culture under 5C conditions. Efficient HBV infection of 5C-PHH was demonstrated by immunostaining for HBV core antigen (HBcAg) (data not shown). Furthermore, 5C-PHH was still susceptible to HBV infection even when the MOI (multiplicity of infection) was reduced to 10. HBV infection could be achieved at MOI=10, indicating that 5C-PHH is a highly susceptible system for HBV infection.
[0067] Importantly, 5C can stably support HBV infection from various sources, including various genotypes of HBV and the in vitro producer cell line HepAD38. 5C-PHH can support the entire HBV life cycle and generate HBV infectious particles.
[0068] In addition, 5C-PHH can also be infected by other hepatitis viruses, such as hepatitis C virus (HCV).
[0069] Hepatocytes cultured by the methods disclosed herein may also be used to textuate the effects of treatment options / novel therapeutic agents for liver disease.
[0070] The data in this application illustrate that hepatocytes cultured as disclosed herein responded to viral therapy. The 5C-PHH infection model was amenable to two classes of clinical anti-HBV drugs.
[0071] The success of inoculating hepatocytes with hepatitis viruses can be extended to other parasites that infect the liver, such as malaria parasites.
[0072] Malaria is a mosquito-borne infectious disease caused by microorganisms belonging to the Plasmodium group that infects humans and other animals. Five species of malaria parasites infect and spread humans. Most deaths are caused by P. falciparum, while P. vivax, P. ovale, and P. malariae generally cause milder forms of malaria. The disease is commonly transmitted by infected female Anopheles mosquitoes. When a mosquito bites, parasites contained in the mosquito's saliva enter the bloodstream of the bitten subject. The parasites migrate to the liver, where they mature and reproduce.
[0073] V.Kit A kit is provided for long-term maintenance of functional hepatocytes in culture. The kit includes an adenylate cyclase activator, a TGFβ inhibitor, a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor (herein, "5C"). The most preferred adenylate cyclase activator is forskolin; the preferred TGFβ inhibitor is SB431542 (SB43); the preferred Notch inhibitor is DAPT; the preferred Wnt inhibitor is IWP2, and the preferred BMP inhibitor is LDN193189. The kit includes instructions for supplementing a basal hepatocyte culture medium with at least an adenylate cyclase activator, a TGFβ inhibitor, a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor. EXAMPLES
[0074] Materials and Methods Isolation and culture of human hepatocytes This study was approved by the Research Ethics Committee of the China-Japan Friendship Hospital (Ethics Approval Number: 2009-50). PHH were obtained from human donors. Human hepatocytes were isolated from discarded human livers. A modified two-step collagenase perfusion method was used to isolate primary human hepatocytes from these tissues (Ootani, et al., Nat Med., 15:701-706 (2009)). Briefly, the liver tissue was perfused with PB (perfusion buffer: 0.15 M NaCl; 5 mM KCl; 25 mM NaHCO3; 5 mM glucose; 20 mM Hepes) to remove remaining blood cells, followed by perfusion with PBE (perfusion buffer + 1 mM EDTA). The tissue was then perfused with PBC (perfusion buffer + 1 mg / mL type IV collagenase, 5 mM CaCl2, Gibco). All buffers were pre-warmed to 37 °C before the isolation steps. Hepatocyte suspensions were harvested, washed with Williams medium E (Gibco), and then filtered through a 40 μm nylon cell strainer (Falcon). The isolated hepatocytes were then plated at 2.5 × 10 cells on collagen type I-coated (rat tail collagen type I, Gibco) plates. 5 / cm 2 The seeds were sown at a density of 1000 x 1000 mm.
[0075] Commercially available hepatocytes: Plateable cryopreserved human hepatocytes (lots: HVN and HNN) were purchased from Bioreclamation IVT (product number: M00995-P).
[0076] Serum-free medium (Null) used for culturing hepatocytes: Williams medium E with B27 (50x, Gibco), Glutmax (Gibco) and PenStrep (Gibco). DMSO vehicle control: Null supplemented with approximately 0.035% DMSO. 5C condition: Null supplemented with forskolin (10 μM), SB431542 (10 μM), IWP2 (1 μM), DAPT (1 μM) and LDN193189 (0.5 μM). Hepatocytes cultured for 24 hours were cultured in the commercially available medium HCM (Lonza).
[0077] Cryopreservation and regeneration of human hepatocytes Hepatocytes were cryopreserved at 1 × 10 cells / mL using a cryopreservation medium containing 60% Williams medium E (Gibco), 30% HypoThermosol FRS (BioLife Solutions), and 10% DMSO (Sigma-Aldrich). 7 The cells were stored frozen at a concentration of 1 mL / vial. The vials were then immediately transferred to a Cryo1°C freezing container (Nalgene) and frozen in a -80°C freezer for 24 hours. The vials were then transferred to liquid nitrogen for long-term storage.
[0078] For regeneration, a cryopreserved hepatocyte vial was thawed in a water bath at 37° C. Then, 1 mL of cell suspension was added to 5 mL of null, followed by centrifugation at 160 g for 5 min at 4° C., and then resuspended in medium. Cell viability was confirmed with trypan blue (Gibco).
[0079] Small molecule compounds and cytokines The small molecule compounds and cytokines used in the screening were purchased or synthesized as described in Table 1. Their concentrations are shown in Table 1.
[0080] [Table 1] TIFF0007594789000009.tif237170 TIFF0007594789000010.tif235170 TIFF0007594789000011.tif226170 TIFF0007594789000012.tif244170
[0081] Drug Metabolic Activity Assay Drug metabolism activity was assessed using a previously described method (Kyffin et al., Toxicol. In vitro. An Int, J. Published in assoc with BBIBRA, 48:262-275 (2018).). Briefly, hepatocytes were harvested as a cell suspension and drug metabolism activity was assessed. 1 × 10 6 The cells were added to the CYP enzymes. Substrate solutions were prepared by adding the substrates individually to the incubation medium. The metabolic reaction was initiated by mixing 250 μL of substrate solution with 250 μL of cell suspension in a 5 mL polystyrene round-bottom tube (BD Falcon). The tube was placed on an orbital shaker set at a shaking speed of 210 rpm in an incubator. After 15–120 min of incubation at 37°C, the reaction tube was centrifuged at room temperature and the supernatant was collected. The drug metabolic reaction was stopped by adding three volumes of methanol to the collected supernatant and freezing at −80°C. To quantify the metabolites, 1% internal standards of each substrate were added and liquid chromatography / mass spectrometry (LC / MS) analysis was performed. The results were normalized to pmol of metabolite formed per minute per million cells. The substrates specific to each CYP enzyme and their concentrations are shown in Table 2. The isotope-labeled reference metabolites and standard metabolites are listed in Table 2.
[0082] [Table 2]
[0083] Preparation of HBV stock HBV virus was obtained from the plasma of a chronic HBV carrier with written consent. HepAD38 cells were cultured in Dulbecco's modified minimal essential medium (DMEM) supplemented with 10% FBS and 0.1 mM non-essential amino acids (NEAA). After 3 days, when the cells reached confluence, the medium was changed to a medium consisting of 3% FBS, 0.1 mM NEAA, and 2% DMSO. Supernatants were harvested every 3 days and fresh medium was added. The harvested medium was pooled and concentrated 100-fold via centrifugation using a centrifugal filter device (Amicon Ultra-15, regenerated cellulose 100.000, Merck Millipore Corp.). The concentrated virus stock was aliquoted and stored at -80°C.
[0084] HBV purification by sucrose density gradient centrifugation was performed as described by Bremer et al. 2009 and Glebe and Gerlich, 2004. Briefly, HBV-infected patient plasma was loaded onto ultracentrifuge tubes containing discontinuous sucrose gradients with densities of 60%, 45%, 35%, 25% and 15%. Sucrose solution was prepared in TNE (20 mM Tris-HCl, 149 mM NaCl, 1 mM EDTA, pH 7.4). The plasma-loaded tubes were then centrifuged at 112,000 g for 15 h in an SW32 rotor (Beckman) at 10°C. After centrifugation, the virus-containing fraction (between 45% and 35% fractions as determined using a real-time PCR-mediated detection kit (KHB, Shanghai, China)) was diluted with TNE and pelleted through 10–15% sucrose at 112,000 g for 15 h in an SW32 rotor. The pellet was resuspended in 2 mL of null medium.
[0085] For CsCl density gradient purification, plasma was loaded onto a CsCl step gradient with a density of 1.1 to 1.5 g / mL (five steps, 2 mL each). After centrifugation at 174,000 g for 35 h at 4°C in an SW41 rotor (Beckman), the gradient fractions were collected and virus-containing fractions were detected by a real-time PCR-mediated kit (KHB, Shanghai, China).
[0086] HBV infection HBV viral infection is characterized by a viral load of 200 genome equivalents, or 1 × 10 5 Cells were seeded at 2 x 10 7 copies of genome equivalents. Inoculation medium was made fresh by first dissolving PEG in null to a final PEG concentration of 4% and without the addition of DMSO. Inoculation volumes were adjusted to the plating format (25 μL (for 384-well plates), 100 μL (for 96-well plates), 500 μL (for 24-well plates)). After 20 h, the inoculum was removed and cells were washed three times with PBS, then after 3 h another three times and cultured in different conditions (Null / DMSO / 5C) with a change of medium every 3 days. Cells were cultured for the indicated times (PEG-free, DMSO-free) and then harvested for further analysis. In some comparative experiments, inoculation was performed at MOI titrations (10 / 50 / 100 / 200 / 400).
[0087] For reinfection, the supernatants of HBV-infected 5C-PHH were harvested and concentrated 100-fold using centrifugal filter devices (Amicon Ultra-15, regenerated cellulose 100.000, Merck Millipore Corp.) via centrifugation at 3,000 g for 1 h at 4°C, and then inoculated into naive PHH using the infection method described above.
[0088] Detection of HBV products HBV viral antigens HBsAg and HBeAg were detected using 50 μL of supernatant from cultured PHHs using a commercially available ELISA kit (Autobio, Zhengzhou, China) according to the manufacturer's instructions.
[0089] For HBV DNA quantification, viral DNA was isolated using the DNeasy Blood & Tissue Kit (QIAGEN, Cat No: 69504). The isolated DNA was quantified using a real-time PCR-mediated detection kit (KHB, Shanghai, China). Viral genome equivalent copies were calculated based on a standard curve constructed with known copy numbers.
[0090] For quantification of HBV-specific RNA, total RNA from HBV-infected cells was isolated using RNeasy Plus Mini Kit (QIAGEN). Approximately 400 ng of total RNA was reverse transcribed into cDNA using TransScript First-Strand cDNA Synthesis SuperMix (TransGen Biotech). Primers 5'-GAGTGTGGATTCGCACTCC-3' and 5-GAGGCGAGGGAGTTCTTCT-3' were used for the HBV 3.5 kb transcript; primers 5'-TCACCAGCACCATGCAAC-3' and 5'-AAGCCACCCAAGGCACAG-3' were used for the total HBV-specific transcript. Amplification of a 123 bp fragment for the 3.5 kb transcript and a 92 bp product for the total HBV-specific transcript were both performed by denaturation at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C for 3 s / cycle and annealing / extension at 60°C for 30 s.
[0091] The cccDNA detection method used in this study was performed. Briefly, DNA was isolated using DNeasy Blood & Tissue Kit (QIAGEN, Cat No: 69504). Extracted DNA was digested with Plasmid-safe ATP-dependent DNase (Epicentre Technologies) for 0.5 h at 37°C and inactivated at 70°C for 30 min. Then, 0.5 μL of the 10 μL reaction was added to a 10 μL real-time PCR reaction. Viral genome equivalent copies were calculated based on a standard curve generated with known copy numbers. Real-time PCR was performed using Power SYBR® Green PCR Master Mix (Applied Biosystems) and run on a CFX384™ Real-Time PCR detection system (Bio-Rad). For Southern blot analysis of HBVcccDNA, HBV DNA was extracted by core DNA extraction method and modified HirtDNA extraction method. For Southern blots, the prepared DNA samples were separated on a 0.8% agarose gel and then transferred to a nylon membrane (Amersham). To confirm the identity of the cccDNA, Hirt DNA preparations from untreated and SpeI-digested 5C-PHH were separated on an agarose gel. HBV DNA fragments of 1.7 kbp, 2.1 kbp, and 3.1 kbp containing a labeled HBV probe (HBV DNA fragments of 370 bp to 705 bp, Southern blot probe) were also run on the same agarose gel and used as molecular markers for relaxed circular DNA (rcDNA), cccDNA, and single-stranded DNA (ssDNA) in Southern blot analysis. Southern blots were performed using the DIG High Prime DNA Labeling and Detection Starter Kit II (Roche, 11 585 614 910).The primer sequences for preparing DNA markers (genotype D: kindly provided by Professor Wenhui Li) were as follows: HBV 3.2 kb marker: HBV-D-EcorI-F 5'-GAATTCCACAACCTTTCACCAAA HBV-D-EcorI-R 5'-GAATTCCACTGCATGGCCTGAGGATGA HBV 2.1 kb marker: HBV-D-EcorI-F 5'-GAATTCCACAACCTTTCACCAAA QYH-2.1 kb-R 5'-CCCAGGTAGCTAGAGTCATTAGT HBV 1.7 kb marker: HBV-D-EcorI-F 5'-GAATTCCACAACCTTTCACCAAA QYH-1.7 kb-R 5'-AAGGTCGGTCGTTGACATTGCAGAGA.
[0092] Detection of HCV infection and HCV products The Huh7.5 cell line was kindly provided by Professor Charles Rice and routinely maintained in Dulbecco's modified medium supplemented with 10% fetal bovine serum (Biological industries), 25 mM HEPES (Gibco) and non-essential amino acids (Gibco). To generate cell cultured HCV, a plasmid encoding HCV Jc1FLAG2 (p7-nsGluc2A) (Jc1G in the text) was first linearized by XbaI digestion and used as a template for in vitro transcription using MEGAscript (Invitrogen). HCVcc was generated by electroporation of in vitro transcribed Jc1G RNA into Huh7.5 cells as previously described. Virus-containing supernatants were harvested daily from day 3 post-electroporation onwards and up to day 7 post-electroporation. Supernatants were combined and virus was concentrated by centrifugation using Amicon® Ultra-15 (100K) centrifugal filter devices (Millipore) at 5000 g for 30 min at 4° C. The buffer was exchanged into PBS by repeated centrifugation using an Amicon® Ultra-15. Concentrated virus was titered in Huh7.5 by limiting dilution.
[0093] To quantify intracellular HCV RNA, cells were lysed in Trizol reagent (Invitrogen). RNA was purified from Trizol extracts and reverse transcribed using PrimeScript™ RT reagent Kit with gDNA Eraser (Perfect Real Time) from TaKaRa according to the manufacturer's instructions. The cDNA samples were subjected to real-time PCR (SYBR® Premix Ex Taq™ Tli RNaseH Plus) using primers for the specific genes listed below (GAPDH: (s) GGT ATC GTG GAA GGA CTC ATG A, (as) ATG CCA GTG GCT TCC CGT TCA GC; HCV: (s) CCC TGT GAG GAA CTA CTG TCT TCA CGC, (as) GCT CAT GGT GCA CGG TCTA CGA GAC CT). Relative RNA levels were calculated using the 2-ΔΔCt method. GAPDH was used as a housekeeping gene for loading normalization.
[0094] To quantify luciferase activity, the supernatant from each well was collected and mixed with an equal volume of 2× passive lysis buffer (Promega). Luciferase activity was measured using Renilla luciferase substrate (Promega) according to the manufacturer's protocol.
[0095] Immunohistochemical and immunofluorescent staining Cells were fixed in 4% paraformaldehyde (DingGuo, AR-0211) for 20 min at room temperature, then permeabilized and blocked with PBS containing 3% normal donkey serum (Jackson Immuno Research, 017-000-121) and 0.25% Triton X-100 (Sigma-Aldrich, T8787) for 60 min at room temperature. Cells were then incubated with primary antibodies overnight at 4°C. Secondary antibodies (Jackson ImmunoResearch) were incubated for 1 h at room temperature. Cell nuclei were stained with DAPI (Roche Life Science, 10236276001). The primary antibodies used are listed in Table 3.
[0096] [Table 3]
[0097] To detect the spread of HBV infection, immunohistochemical staining for HBcAg was performed. Briefly, cells were fixed with 3.7% paraformaldehyde for 10 min at room temperature. After PBS washing, cells were treated with 50% ethanol in distilled water, then 70% ethanol in distilled water for at least 1 h at 4 °C. After at least 2 h of blocking (blocking solution: PBS with 10% FBS), cells were incubated with anti-HBcAg (diluted 200-fold in blocking solution) overnight at 4 °C. Primary antibodies were washed off, and cells were treated with post-primary for 30 min at room temperature. Cells were incubated with secondary antibodies for 30 min at room temperature. Staining media was freshly made by diluting DAB 50-fold with DAB diluent, and then 150 μL of substrate solution was added to each well. After DAB reaction, cells were counterstained with hematoxylin for 5–10 min.
[0098] qRT-PCR Total RNA was isolated using RNeasy Micro Kit (QIAGEN). RNA was converted to cDNA using First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen). PCR was performed using Power SYBR® Green PCR Master Mix (Applied Biosystems) and run using the MX3000P Sequence Detection System (Stratagene). Data were analyzed using the ΔΔCt method. Primers used for qRT-PCR are listed in Table 4.
[0099] [Table 4]
[0100] RNA sequencing Total RNA was isolated using the RNeasy Plus Mini Kit (QIAGEN). Libraries for RNA sequencing were constructed using the Illumina mRNA-Seq Prep Kit (Illumina). Fragmented and randomly primed 150 bp paired-end libraries were sequenced using an Illumina HiSeq 4000.
[0101] Software and algorithms used for transcriptome analysis include Cutadapt 1.16 (http: / / cutadapt.readthedocs.io / en / stable / guide.html), Salmon 0.8.2 (https: / / combinelab.github.io / salmon / ), and R 3.5.0 (https: / / www.r-project.org). Expression profiles of HepG2, F-PHH-3 and F-PHH-4 were downloaded as raw data. Expression profiles of PHH0d, hiPSC-Hep rep1, hiPSC-Hep rep2, hiPSC-Hep rep3 and hiPSC-Hep rep4 (Gordillo, et al., Development, 142:2094-2108 (2015)) were downloaded from the GEO database (GSM2817112, GSM2753376, GSM2753377, GSM2753378, GSM2753379) as raw sequence reads. To compare gene expression profiles between paired-end and single-end libraries, we used read 1 from the paired-end reads we generated. Read 1 and the downloaded single-end reads were trimmed to the same 40bp length using Cutadapt. Expression values of each sample were quantified by Salmon. Unsupervised hierarchical clustering of RNA-seq data was generated by the hclust package in R.
[0102] Biochemical assays Human albumin was measured using a Human Albumin ELISA Quantitation Kit (Bethyl Laboratories). Urea concentration was measured by QuantiChrom™ Urea Assay Kit (BioAssay Systems). MTT assays were performed at the indicated time points according to the manufacturer's instructions (Vybrant® MTT Cell Proliferation Assay Kit, Invitrogen).
[0103] statistical analysis Two-tailed, unpaired t-tests were used for statistical analysis. Results are expressed as mean ± SEM, where n indicates the number of replicates from the same batch of PHH. p-values are as follows: *p<0.05; **p<0.01; *** p<0.001; **** p<0.0001.
[0104] Results and Discussion A novel chemical strategy using a combination of small molecules was developed to maintain PHHs for extended periods in vitro. Small molecules confer the advantage of synergistically orchestrating innate signals in cultured cells due to their ability to achieve flexible spatiotemporal regulation of specific cellular targets. To identify small molecules that promote the maintenance of PHHs, we first used RNA sequencing (RNA-Seq) to compare the global gene expression profile of freshly isolated primary human hepatocytes (F-PHHs) with hepatocytes cultured in vitro for only 24 h. In line with previous studies, key hepatocyte function genes were dramatically downregulated after 24 h of culture (Figure 1). Notably, expression of key components of the TGF-β signaling pathway was upregulated in hepatocytes cultured for 24 h (Figure 2A).
[0105] Previous studies have shown that TGF-β signaling is a major inducer of epithelial-mesenchymal transition (EMT) for hepatocytes. Therefore, we used the TGF-β inhibitor SB431542 (SB43) to block TGF-β signaling-induced EMT, and with SB43 treatment, cultured hepatocytes maintained epithelial morphology with E-cadherin expression even after 2 weeks (data not shown). However, blocking TGF-β signaling could not suppress the expression of EMT-related transcription factors snail family transcriptional repressor 2 (SNAI2); twist-associated protein 1 (TWIST1), and could not rescue the expression of liver function genes (ALB; CPS1 (carbamoyl phosphate synthetase 1); CYP3A4 and CYP1A2) (Figure 2B), indicating that blocking TGF-β signaling partially suppresses EMT but has limited effect on maintaining the functional state of PHH.
[0106] To identify other signaling pathways important for maintaining functional PHHs, we screened a chemical library of small molecules by adding individual small molecules in combination with SB43 to cultured hepatocytes. Forskolin (FSK), an activator of adenylate cyclase (AC), maintained liver function gene expression (ALB; CSP1; CYP3A4; OATP1B1), downregulated α-smooth muscle actin (ASMA) EMT marker gene expression (Figures 3A and 3B), and maintained PHH survival with maintenance of liver morphology. Under these two chemical conditions containing FSK and SB43 (herein, "2C"), we observed that hepatocytes exhibited typical hepatic polarized polygonal morphology and rare cell death after 2 weeks of culture. In contrast, in the absence of FSK and SB43, hepatocytes became morphologically depolarized within 2 weeks, and the viability of cultured cells was low.
[0107] PHHs maintained under 2C conditions for a long period of time (2C-PHHs) have the functional properties of their freshly isolated counterparts Studies were performed to test whether 2C conditions could maintain the function of PHH in the long term. We first assessed the expression of a panel of important liver function markers, including serum proteins synthesized and secreted in the liver (ALB and ApoC1), rate-limiting enzymes of nitrogen metabolism (NAGS, CPS1 and OTC), key pharmacokinetic metabolic cytochrome P450 (CYP) enzymes (CYP3A4, CYP2D6 and CYP2C9) and transporters (NTCP, MRP2 and BSEP). By RT-qPCR analysis, the expression of these genes was comparable between 2C-PHH and F-PHH (Figure 4B). Furthermore, a broad spectrum of other liver function genes was analyzed, such as genes involved in amino acid and fatty acid metabolism as well as coagulation. The results showed that the gene expression profile of 2C-PHH was similar to that of F-PHH. To further confirm that 2C was functionally independent of basal medium type, 2C was tested in both WME and HCM. RT-qPCR analysis showed that after 4 weeks of culture, 2C-PHH treated with 2C expressed hepatic genes at levels comparable to F-PHH in both HCM and WME (Figure 4C; lower panel). This result indicates that 2C acts independently of the type of culture medium, and the following experiments are based on WME. Importantly, FSK combined with SB43 showed synergistic effects on hepatocyte maintenance (measured as upregulation of ALB; N-acetylglutamate synthase (NAGS), apolipoprotein CI (APOC1); CYP2D6; NTCP expression; and downregulation of SNAI2 and TWIST1 in FSK+SB43 treatment compared to FSK or SB43 alone) potentially by activating cAMP (Figure 4A-D).
[0108] Taken together, these data indicate that 2C conditions effectively maintained the expression of key liver function genes in long-term cultured PHHs.
[0109] Next, we quantified albumin (ALB) secretion, which indicates the capacity for protein synthesis and secretion, and urea synthesis, which indicates the capacity for nitrogen metabolism, in human hepatocytes. ALB secretion dramatically decreased within one week in hepatocytes without 2C, but was well maintained for about four weeks in 2C-PHH. Similar results were obtained for urea synthesis. These results were reproducible in different batches of PHH (Figure 4E).
[0110] The in vivo engraftment ability of 2C-PHH was tested. After 4 weeks, 2C-PHH robustly re-engrafted into the liver of transplanted mice and secreted human serum albumin (HSA) at levels comparable to F-PHH. In contrast, hepatocytes cultured without 2C poorly re-engrafted into the mouse liver, as shown by the fact that 2 weeks after transplantation, HSA was undetectable, and 4 weeks after transplantation, HSA levels were barely detectable in contrast to 2C-PHH (Figure 4J). Collectively, these data demonstrated that 2C can support the functional maintenance of PHH in vitro for at least 4 weeks.
[0111] Maintenance of drug-metabolizing capacity of hepatocytes cultured under 2C conditions To evaluate the drug metabolism capacity of 2C-PHH, the expression of key CYP enzymes was quantified by RT-qPCR. After 1 month of culture, the expression of CYP3A4, CYP1A2, CYP2C9, CYP2D6, CYP2B6, and CYP2C19 in 2C-PHH was comparable to that in F-PHH (Figure 4). To further evaluate the drug metabolism activity, a liquid chromatography mass spectrometry (LC / MS) assay was used. The data showed that after 1 month of culture, the metabolic activities of CYP3A4, CYP2D6, CYP2C9, and CYP1A2 in 2C-PHH, which are involved in more than 80% of human drug oxidation, were comparable to those in F-PHH, while hepatocytes cultured without 2C lost these metabolic activities (Figure 4F).
[0112] Further experiments were performed to test whether 2C-PHH could be applied to predict drug-drug interactions (DDIs). Potent CYP enzyme inhibitors and inducers commonly used in DDI studies were applied (Baranczewski et al., PR, 58:453-472, (2006)), and the results showed that 2C-PHH responded effectively to these inhibitors and inducers (Figure 4G, Figure 4H, and Figure 4I). The drug metabolism activity of 2C-PHH was dramatically suppressed by CYP enzyme-specific inhibitors (Figure 4I). In addition, after one month of culture, the gene expression levels and metabolic activities of three major CYP enzymes, CYP3A4, CYP1A2, and CYP2B6, in 2C-PHH responded well to specific inducers (Figure 4G and Figure 4H). Taken together, these data suggest that 2C can support the maintenance of drug metabolism activity of PHH in vitro.
[0113] Maintenance of cryopreserved and regenerated hepatocytes by 2C with additional small molecules Considering that 2C allows for robust functional maintenance of PHH for a long period of time, we then tested whether 2C could support the maintenance of cryopreserved primary human hepatocytes (Cryo-PHH), the main source of human hepatocytes in applications. However, Cryo-PHH are more difficult to stably maintain in vitro due to poor viability and functionality resulting from the cryopreservation process (Donato et al., Current Drug Metabolis, 9:1-11 (2008b)). We observed improved viability of cultured Cryo-PHH under 2C conditions. However, polygonal morphology was lost after 4 weeks of culture (data not shown), suggesting that EMT had occurred in 2C-treated Cryo-PHH.
[0114] Based on this combination of SB43 and FSK, further chemical screening was performed to show that DAPT (Notch inhibitor), IWP2 (Wnt inhibitor) and LDN193189 (BMP inhibitor) further blocked the expression of EMT marker genes (collagen type I alpha 1 (COL1A1); thymocyte antigen 1 (Thy1); vimentin (VIM)) (Figure 5A-5C). Notably, small molecules or cytokines targeting the same signaling pathways led to similar suppression of EMT genes (Figure 5D). This minimal condition consisting of five chemicals (5C), FSK, SB43, DAPT, IWP2, and LDN193189, effectively blocked the expression of EMT genes in cultured cryopreserved primary human hepatocytes (Cryo-PHH) (Figure 6A and Figure 5E) (expression of COL1A1, a typical biomarker of mesenchymal lineage, was effectively downregulated after 5C treatment), and supported the maintenance of the typical polygonal shape of both F-PHH and Cryo-PHH over a 4-week period (data not shown). Furthermore, PHH cultured in 5C (5C-PHH) expressed surrogate liver function markers (ALB, AAT (α1-antitrypsin), CPS1, CYP3A4; CYP1A2) along with polarization after 4 weeks of culture, as measured by deposition of CDFDA at cell-cell borders (data not shown). Albumin secretion and urea synthesis in 5C-PHH were also maintained for at least 3 weeks and were reproducible across nine batches of PHH (Figure 6B-E).Interestingly, a batch of highly viable PHH could be functionally maintained for 2 months under 5C conditions.
[0115] Next, a time course analysis of global gene expression profiling was performed by RNA sequencing of 5C-PHH over a period of one month from isolation. A commonly used hepatocyte culture condition (Dunn, et al., Biotechnol. Prog., 7:237-245 (1991)), sandwich culture method (i.e., culture of hepatocytes between two layers of gelled collagen), was analyzed for comparison as well. Hierarchical clustering illustrated that after 12 hours of long-term culture, the transcriptome of PHH in sandwich culture was similar to that of the null and DMSO groups, but only 5C-PHH clustered with F-PHH. Of note, sandwich culture was not combined with 5C. The ability of 5C conditions to support global hepatic gene expression was reproducible in another three independent batches of PHH (Figure 7). Furthermore, qRT-PCR analysis confirmed that 5C conditions were more effective in maintaining the expression of surrogate hepatocyte functional markers and suppressing the expression of mesenchymal marker genes compared to the sandwich method (Figure 8A). 5C also efficiently maintained the expression of transcription factors that play important roles in hepatocyte function (Figure 8B). Collectively, these results demonstrated that 5C conditions can maintain the global gene expression pattern of human hepatocytes in vitro for a long period of time.
[0116] Hepatocytes are known to be important in the metabolism and detoxification of exogenous drugs; however, the metabolic activity of CYP in hepatocytes is rapidly lost in culture (Figure 1). In the disclosed 5C system, PHH cultured for 4 weeks was found to express core CYP enzymes at a level equivalent to that of F-PHH. Furthermore, the major phase II drug metabolism enzymes and phase III drug metabolism-related transporters in 5C-PHH were expressed at the same level as those in F-PHH (Figures 8D and 8E). These data suggested that 5C effectively maintained the expression of drug metabolism genes.
[0117] We next characterized key CYP enzymes, including CYP3A4, CYP1A2, CYP2C9, CYP2D6, and CYP2B6, which are involved in the metabolism of approximately 80-90% of clinical drugs in humans. Liquid chromatography-mass spectrometry showed that after 2 weeks of culture, the metabolic activities of these key enzymes in 5C-PHH were comparable to those in F-PHH (Figure 8F). In contrast, the metabolic activity of PHH cultured in the control group was barely detectable (Figure 8F). These results were reproducible in three different batches of PHH. Taken together, these results indicated that 5C maintains the drug metabolic activity of cultured human hepatocytes in vitro.
[0118] The robust functional maintenance of human hepatocytes by 5C culture conditions provides a platform for modeling HBV infection in vitro. qRT-PCR analysis confirmed comparable expression levels of NTCP between F-PHH and PHH cultured under 5C conditions for 4 weeks (Figure 9A). Successful HBV infection was then achieved by inoculating PHH with plasma from an HBV-infected patient, with HBV products (secreted HBsAg, HBeAg and DNA particles) detected in the supernatant of 5C-PHH cultures (Figure 9B and Figure 9D). The levels of intracellular HBV-3.5kb and HBV total RNA transcripts also increased over time (Figure 9C). High levels of HBV product production were sustained in 5C-PHH for at least 1 month. Importantly, the formation of HBVcccDNA was detectable by Southern blot in 5C-PHH (Figure 9H), and qPCR analysis showed that cccDNA was persistently detectable over 4 weeks of culture under 5C conditions (Figure 9E). Efficient HBV infection of 5C-PHH was demonstrated by immunostaining for HBV core antigen (HBcAg) (data not shown). Furthermore, 5C-PHH was susceptible to HBV infection even when the MOI was reduced to 10 (Figures 10A and 10B). HBV infection supported by 5C was well reproduced in additional batches (>5 batches) of PHH containing Cryo-PHH (Figures 11A-11E). Importantly, 5C was able to stably support HBV infection from various sources, including various genotypes of HBV and the in vitro producer cell line HepAD38 (Figures 11A-11D).
[0119] Viral particles were collected from the supernatant of HBV-infected 5C-PHH and used to inoculate naive PHH. HBeAg and HBV DNA were detected in PHH inoculated with the supernatant of HBV-infected 5C-PHH (Fig. 9F-G), indicating that 5C-PHH could support the entire HBV life cycle and generate HBV infectious particles. Furthermore, the percentage of HBV-infected 5C-PHH increased with the extension of the incubation time (data not shown; Fig. 11E), suggesting the possibility of HBV spread by cell-to-cell infection and / or de novo infection of HBV particles.
[0120] The 5C-PHH infection model was found to be sensitive to two classes of clinical anti-HBV drugs: interferon-α (IFN-α) and nucleoside (nucleotide) reverse transcriptase inhibitors, such as entecavir (ETV) and lamivudine (LAM). Treatment of HBV-infected 5C-PHH with all three drugs (ETV, LAM, and IFN-α) resulted in a reduction of HBV products (Figures 12A-D). Similar results were obtained in cryopreserved PHH cultured in 5C, with a significant reduction in cccDNA by IFN-α. Furthermore, interferon-stimulated genes (ISGs) were significantly upregulated in long-term cultured 5C-PHHs when treated with IFN-α but responded weakly to HBV infection, consistent with a previous report that HBV evades hepatocyte innate immunity (Cheng, et al., Hepatol., 66:1779-1793 (2017)) (Figure 13A).
[0121] Furthermore, we compared the culture conditions with other reported culture conditions for long-term HBV infection in PHH (Lucifira, et al., Science, 343:1221-1228 (2014), Winner, et al., Nat. Comm., 8:1256 (2017), Xia, et al., J. Hepatol., 656:494-5603 (2017)) and found that 5C exhibited clear advantages, especially in long-term maintenance of liver function and stable support of HBV infection (data not shown; Figures 13B, 13C, and 13D). Importantly, the 5C conditions can be miniaturized into a microwell format and are applicable to high-throughput applications (Figures 14A-C). Furthermore, these results establish 5C as a simple, yet highly effective and stable culture condition for long-term maintenance of PHH in vitro and are of great value for the study of HBV infection.
[0122] In addition to HBV, 5C-PHH can be infected with other hepatitis viruses, such as hepatitis C virus (HCV). 5C-PHH was exposed to infectious viral particles of HCVJc1G expressing a secreted Gaussia luciferase (Gluc) reporter. Viral replication was detected in 5C-PHH and effectively blocked by DCV, a direct-acting antiviral drug for hepatitis C treatment (Figures 15A and 15B). Unlike HBV, HCV induced robust ISG expression in 5C-PHH (Figure 15C). Taken together, these results indicate that 5C-PHH serves as a valid model for modeling hepatotropic infection and studying antiviral strategies.
[0123] In summary, a chemical approach was developed to maintain the function of primary human hepatocytes for a long period of time. Using this platform, persistent HBV infection spanning the entire viral life cycle in PHH and releasing progeny virus in vitro was demonstrated. Notably, the formation of HBVcccDNA was captured in PHH, which is the key for HBV to re-enter the viral life cycle and induce HBV recurrence in human liver. This platform is simple and easily applicable to high-throughput screening for compounds targeting cccDNA to devise new antiviral strategies, particularly those that may be essential for finding a cure for chronic hepatitis. Methodologically, small molecules have highly tunable functionality that precisely balances cellular signals and modulates molecular networks to stabilize the cellular identity and functionality of mature cells, a strategy that may be extendable to the maintenance of other functional cell types.
[0124] Global gene expression in hepatocytes cultured under 2C and 5C conditions To monitor the dynamic gene expression changes of PHHs during the entire culture process, two different batches (B1 and B2) of hepatocytes cultured with or without 2C and 5C, respectively, were harvested at days 1.5, 3, 5, 8, 15, and 27 for gene expression profiling by RNA-seq. Both F-PHHs and Cryo-PHHs were used as positive controls. Hierarchical clustering illustrated that 2C-PHHs and 5C-PHHs had global gene expression profiles comparable to their freshly isolated counterparts (data not shown). Similar to functional maintenance, the results showed that 2C and 5C conditions maintained the expression of key transcription factors (TFs) of hepatocytes, with expression levels comparable to those of F-PHHs (data not shown). These data indicate that 2C / 5C supports long-term maintenance of the global gene expression profile of cultured PHHs as well as F-PHHs.
[0125] Both cAMP-PKA and cAMP-EPAC are essential for the maintenance of PHH To explore the potential mechanisms underlying our chemical conditions, FSK and SB43, a combination of core small molecules that maintain human hepatocytes, were replaced with their analogs that either block or stimulate the same signaling pathways. Meanwhile, the gene expression repertoire of cultured hepatocytes was profiled by RNA sequencing. Hierarchical clustering analysis showed that FSK plays a central role in maintaining PHH (data not shown). NKH477 (cAMP agonist) and db-cAMP (cAMP analog) replaced FSK and maintained the global gene expression of PHH. In contrast, hepatocytes treated with 1,9-dideoxyforskolin (1,9-dFSK), an inactive analog of FSK, induced an expression profile similar to that of the control group without FSK. The effects of db-cAMP on hepatic marker gene expression, ALB secretion, and urea synthesis were investigated (data not shown). These data indicated that FSK was a small molecule essential for the maintenance of PHH and functioned through the activation of AC (data not shown).
[0126] The downstream targets of cAMP were further investigated. The results showed that inhibition of either PKA or EPAC individually enhanced the expression of mesenchymal markers, suggesting the occurrence of EMT during hepatocyte culture (data not shown). Furthermore, activation of either PKA or EPAC alone could not fully compensate for the withdrawal of FSK from 2C (data not shown). These data suggest that cAMP may be a central signaling hub of the synergistic but non-redundant downstream pathways of PKA, EPAC, and cAMP in maintaining PHH.
[0127] A chemical cocktail that promotes functional maturation of hESC-derived hepatocytes Considering that 2C can maintain the mature function of human hepatocytes, a study was performed to test whether the disclosed chemical culture conditions could promote the maturation of human embryonic stem cell-derived hepatocytes (hESC-Heps). hESC-Heps were generated using a modification of an established protocol (Zhao et al., Cell Res., 23:157-161 (2013)). Immunofluorescence analysis showed that hESC-Heps expressed hepatocyte-specific TFs FOXA2, HNFA4, HNF6, PROX1, and CEBPA (data not shown). Albumin was detected in hESC-Hep. hESC-Hep was immunopositive for AFP and ALB (data not shown) and CYP3A4, but not for CYP1A2, CYP2C9, CYP2A6, and CYP2E1 (data not shown). These data indicated the fetal-like functional characteristics of hESC-Hep.
[0128] In contrast, after hESC-Heps were transferred to 2C conditions, hESC-Heps acquired a polygonal-like morphology with a small nucleus-cytoplasmic ratio (data not shown). Furthermore, liver function marker genes (HNFA4, HNF6, PROX1, CEBPA, CYP2C9, CYP2A6, CYP1A2, etc.) were gradually upregulated from day 7 of culture in 2C (data not shown and Figure 16). Notably, intercellular bile canaliculi were formed after 2 weeks of culture (data not shown) and had reduced AFP expression (data not shown). Importantly, hESC-Heps cultured in 2C expressed a spectrum of CYP enzymes, including CYP3A4, CYP1A2, CYP2C9, CYP2C19, CYP2A6, and CYP2E1 (data not shown). PXR and CAR, two important nuclear receptors related to drug metabolism, were significantly upregulated under 2C conditions (Figure 16). Under 2C conditions, expression of HNF4A, a master regulator of adult hepatocyte-specific genes, was observed, and the expression of maturation factors including CEBPA, PROX1, and ATF5 was increased. Other hepatocyte-specific genes were gradually decreased without 2C treatment (Figure 16). Taken together, these data indicate that the disclosed chemical conditions for adult hepatocytes promoted the functional maturation of hPSC-Hep in a manner close to that of mature hepatocytes.
Claims
1. A supplemented hepatocyte culture composition for maintaining functional hepatocyte function in vitro for an extended period of at least two weeks, comprising at least one factor selected from the group consisting of an adenylate cyclase activator, a TGFβ inhibitor, a Notch inhibitor, a Wnt inhibitor, and a BMP inhibitor, wherein the factor is present in an amount effective to maintain functional hepatocyte function in vitro for an extended period of at least two weeks, as measured as an increase in expression of at least one hepatocyte marker, compared to hepatocytes cultured in an unsupplemented culture composition not comprising an adenylate cyclase activator and a TGFβ inhibitor, after at least two weeks of in vitro hepatocyte culture in the supplemented hepatocyte culture composition. The supplemented hepatocyte culture composition comprises a combination of an adenylate cyclase activator and a TGFβ inhibitor.
2. The composition of claim 1 , further comprising at least one Notch inhibitor, one Wnt inhibitor, and one BMP inhibitor.
3. The composition of claim 1 or 2, wherein the hepatocytes are human hepatocytes or induced hepatocytes (iHep).
4. 4. The composition of any one of claims 1 to 3, comprising a combination of at least one adenylate cyclase activator, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and one BMP inhibitor ("5C").
5. The composition according to any one of claims 1 to 4, wherein the adenylate cyclase activator is forskolin.
6. The composition according to any one of claims 1 to 4, wherein the TGFβ inhibitor is SB431542 (SB43).
7. The composition of any one of claims 1 to 4, wherein the Notch inhibitor is DAPT.
8. The composition of any one of claims 1 to 4, wherein the Wnt inhibitor is IWP2.
9. The composition according to any one of claims 1 to 4, wherein the BMP inhibitor is LDN193189.
10. 10. The composition of any one of claims 1 to 9, wherein the hepatocyte functional protein is selected from the group consisting of albumin (ALB), CPS1, ARG, NAGS, PXR, CAR, APOA2, APOB, F2, F10, cytochrome P450 (CYP) 3A4, CYP1A2, CYP2C9, CYP2D6, NTCP, PXR, CAR, and UGT2B7.
11. The composition of any one of claims 1 to 10, wherein the hepatocytes express at least six hepatocyte functional proteins at the same levels as freshly isolated primary hepatocytes (F-PHH) from the same organism after at least 60 days of culture.
12. The composition of any one of claims 1 to 10, wherein the hepatocytes express at least six hepatocyte functional proteins at the same levels as F-PHH from the same organism after at least 90 days of culture.
13. A method for in vitro culture of functional hepatocytes for a long period of at least 2 weeks by using the composition according to any one of claims 1 to 9.
14. The method of claim 13, wherein the hepatocytes have at least one characteristic selected from the group consisting of hepatocyte morphology (polygonal shape), established hepatocyte functions such as albumin secretion and urea synthesis, and expression of at least one known hepatocyte marker after at least two weeks of in vitro culture.
15. 15. The method of claim 14, wherein the hepatocytes have at least one characteristic after 3 to 8 weeks of culture.
16. At least one hepatocyte marker is selected from the group consisting of cytochrome P450 (CYP) 3A4; CYP1A2; CYP2C9; CYP2D6; CYP2B6; CYP2C19; UDP-glucuronosyltransferase (UGT) 1A3; UGT1A4; UGT2B15; UGT2B7, NTCP(Na + ABCG2 (ATP-binding cassette superfamily G member 2); MRP2 (multidrug resistance-associated protein 2); and organic anion transporting polypeptide (OATP) 1B1.
17. The method of any one of claims 13 to 16, wherein the hepatocytes express at least one of the listed hepatocyte markers at a level equivalent (measured as without statistical significance) or higher when compared to the level expressed by freshly isolated hepatocytes from the same organism.
18. 18. The method of any one of claims 13 to 17, wherein the hepatocytes express at least one, at least two, at least three, at least four, at least five, or at least six of the following hepatocyte markers: APOA2, APOB, F2, F10, CYP3A4, CYP1A2, CYP2C9, and UTG2B7 at levels equivalent (measured as no statistically significant difference) to freshly isolated hepatocytes from the same organism over 90 days of culture.
19. 19. The method of any one of claims 13 to 18, wherein the hepatocytes express metabolically active CYP3A4, CYP1A2, CYP2C9, CYP2D6 and CYP2B6 at levels equivalent to those of F-PHH (measured as without statistical significance) after 2 weeks of culture.
20. Cultivating functional hepatocytes in vitro for a long period of at least 2 weeks by using the composition according to any one of claims 1 to 9; inoculating said cultured functional hepatocytes with a hepatic parasite for a period of time effective for parasite infection; and Cultivating the parasite-infected cells in vitro in a supplemented hepatic basal medium for hepatocyte culture (HC). A method for producing an in vitro liver parasite infection model comprising:
21. The method of claim 20, wherein the parasite is a hepatitis virus, the method comprising inoculating hepatocytes cultured by the method of claim 13 with the hepatitis virus for a time effective for viral infection, and culturing the virus-infected cells in vitro in a supplemented hepatic basal medium for hepatocyte culture (HC).
22. 22. The method of claim 21, wherein the hepatitis virus is hepatitis B, hepatitis D or hepatitis C.
23. The method of claim 21, comprising covalently closed circular DNA (cccDNA) of HBV upon 4 weeks of in vitro culture.
24. 21. The method of claim 20, wherein the parasite is a malaria parasite selected from the group consisting of P. falciparum, P. vivax, P. ovale, and P. malariae.
Citation Information
Patent Citations
JPP6968347B
Specific medium for long-term maintenance and proliferation subculture of human hepatocytes and culture method
US20170198254A1
Liver cells and liver non-parenchymal cells, and methods for preparation thereof
WO2016148216A1
